Neuromics/OPG/PR27029/10 ug

Osteoprotegerin,whichisamemberofthetumornecrosisfactorreceptorsuperfamilyandisinvolvedintheregulationofbonemetabolism.OPGanditsligand(OPGL)arecytokinesregulatingosteoclasto-genesis.OPGLbindstoreceptorsonthesurfaceofpreosteoclastsandstimulatestheirdifferentiationintoactiveosteoclasts.Thisleadstoosteoresorption.OPGinhibitsthisosteoclasto-genesis(OPGissecretedbyosteoblasts,andbindstoOPGL,thusinhibitingmaturationofosteoclastsandosteoresorption).ThedegreeandactivityofosteoresorptiondependmainlyonthebalancebetweenOPGanditsligand(OPGL);factorsincreasingOPGLexpressionmostlyreduceOPGexpressionandviceversa.

Reference:

1.Effectsofhypolipemicdrugsontheosteoprotegerin-sRANKLsysteminpatientswithcoronaryarterydisease. ThrombHaemost2007May;97(5):868-70

2.Plasmaosteoprotegerinlevelsinthegeneralpopulation:relationtoindicesofleftventricularstructureandfunction. Hypertension2007Jun;49(6):1392-8

3.Thesex-specificassociationofserumosteoprotegerinandreceptoractivatorofnuclearfactorkappaBlegendwithbonemineraldensityinolderadults:theRanchoBernardostudy. EurJEndocrinol2007May;156(5):555-62

4.Thyroidhormonedeficiencyandpostmenopausalstatusindependentlyincreaseserumosteoprotegerinconcentrationsinwomen. EurJEndocrinol2007May;156(5):539-45

5.Abnormalboneremodelingprocessisduetoanimbalanceinthereceptoractivatorofnuclearfactor-kappaBligand(RANKL)/osteoprotegerin(OPG)axisinpatientswithsolidtumorsmetastatictotheskeleton.
ActaOncol2007;46(2):221-9

6.Inhibitionoftoothmovementbyosteoprotegerinvs.pamidronateunderconditionsofconstantorthodonticforce. EurJOralSci2007Apr;115(2):131-6